GlassScriptPhysician profile
Jonathan Fialkow
NPI 1538176557
$153,418.94
in general payments reported to CMS, 2019-2025
30 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $35K · 2021: $29K · 2022: $14K · 2023: $1,100 · 2024: $475 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.97 |
| Education | $146.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $71,440.92 | 2019-2022 | |
| Amgen INC. | $40,964.42 | 2019-2023 | |
| Esperion Therapeutics, INC. | $26,478.97 | 2020-2021 | |
| Pfizer INC. | $3,530.24 | 2019-2024 | |
| Novo Nordisk INC | $3,486.75 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $3,266.90 | 2022-2025 | Cobalt Dr Mri Surescan, Symplicity G3, Abre |
| Astrazeneca Pharmaceuticals LP | $1,000.00 | 2022 | |
| Medtronic Vascular, INC. | $906.33 | 2019-2020 | |
| Cleerly, INC. | $491.60 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Boston Scientific Corporation | $367.33 | 2023-2025 | Watchman Flx, General - Therapies |
| Braemar Manufacturing, LLC | $294.12 | 2019 | |
| Lilly USA, LLC | $246.15 | 2022-2025 | Zepbound, Mounjaro, Amyvid |
| Impulse Dynamics (USA) INC. | $210.64 | 2023 | Optimizer, Optimizer |
| Philips North America LLC | $173.91 | 2025 | Ecc Solutions |
| Heartflow, INC. | $163.84 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $125.00 | 2023 | Watchpatone |
| Gilead Sciences, INC. | $68.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $48.19 | 2019-2023 | |
| Current Health, INC. | $25.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.51 | 2019-2020 | |
| Abbott Laboratories | $21.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.48 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $18.99 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $17.48 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.32 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fialkow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.